Legato Capital Management
RAPP icon

Legato Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Legato Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-21,124
Closed -$880K – 828
2026
Q2 		$880K Buy
+21,124
New +$776K 0.07% 381

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

Legato Capital Management's RAPP Position: Q3 2026 in Review

Legato Capital Management sold out of Rapport Therapeutics (RAPP) in Q3 2026, closing a stake of 21,124 shares — an estimated $880K sold.

Legato Capital Management first reported a position in RAPP in Q2 2026 and held it in 1 quarter. The position peaked at $880K in Q2 2026. 114 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Legato Capital Management reported no remaining Rapport Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Legato Capital Management sold 21,124 Rapport Therapeutics shares in Q3 2026, an estimated $880K.
  • Legato Capital Management first reported a position in Rapport Therapeutics in Q2 2026 and held it in 1 quarter.
  • Legato Capital Management's Rapport Therapeutics position peaked at $880K in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.